PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30396978-5	2018	RESULTS: Patients with ETS had longer progression-free survival (PFS) than those without ETS [hazard ratio (HR)=0.69] and ETS tended to be observed in the EGFR group, while patients with EOMR had longer PFS than those without EOMR (HR=0.64) and EOMR tended to be observed in the BEV group.	ets	23-26	epidermal growth factor receptor	Homo sapiens	155-159	
27878357-6	2017	RESULTS: Pooled data revealed that the occurrence of ST and ETS >=20% (v < 20%) during anti-EGFR MoAb treatment were both associated with better OS, PFS and ORR.	ets	60-63	epidermal growth factor receptor	Homo sapiens	98-102	
28463756-14	2017	ETS represents an early parameter associated with the benefit from anti-EGFR, while this was not the case with vascular endothelial growth factor A blockade.	ets	0-3	epidermal growth factor receptor	Homo sapiens	72-76	
27878357-9	2017	ETS was also a predictor for absolute survival benefit acquired from additional anti-EGFR treatment for patients with wild-type KRAS tumors, and the more early shrinkage the tumor was, the much benefit was observed.	ets	0-3	epidermal growth factor receptor	Homo sapiens	85-89